Zhixiang Wu

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Transcription Factor

Top Venues

British journal of cancer

Journal of experimental & clinical cancer research : CR

This page only lists publications with an associated author ORCID identifier.

Publications

Xiaoxiao Hu, Yilu Zhou, Charlotte Hill, Kai Chen, Cheng Cheng, Xiaowei Liu, Peiwen Duan, Yaoyao Gu, Yeming Wu, Rob M Ewing, Zhongrong Li, Zhixiang Wu, Yihua Wang
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification. British journal of cancer (2024)
Xiaoxiao Hu, Yilu Zhou, Charlotte Hill, Kai Chen, Cheng Cheng, Xiaowei Liu, Peiwen Duan, Yaoyao Gu, Yeming Wu, Rob M Ewing, Zhongrong Li, Zhixiang Wu, Yihua Wang
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification. British journal of cancer (2024)
Xiaoxiao Hu, Yilu Zhou, Charlotte Hill, Kai Chen, Cheng Cheng, Xiaowei Liu, Peiwen Duan, Yaoyao Gu, Yeming Wu, Rob M Ewing, Zhongrong Li, Zhixiang Wu, Yihua Wang
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification. British journal of cancer 130 (11) (2024)
Xiaoxiao Hu, Yilu Zhou, Charlotte Hill, Kai Chen, Cheng Cheng, Xiaowei Liu, Peiwen Duan, Yaoyao Gu, Yeming Wu, Rob M Ewing, Zhongrong Li, Zhixiang Wu, Yihua Wang
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification. British journal of cancer 130 (11) (2024)
Xiaoxiao Hu, Yilu Zhou, Charlotte Hill, Kai Chen, Cheng Cheng, Xiaowei Liu, Peiwen Duan, Yaoyao Gu, Yeming Wu, Rob M Ewing, Zhongrong Li, Zhixiang Wu, Yihua Wang
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification. British journal of cancer 130 (11) (2024)
Xiaowei Liu, Yuanxia Cai, Cheng Cheng, Yaoyao Gu, Xiaoxiao Hu, Yeming Wu, Yeming Wu, Zhixiang Wu
PCLAF promotes neuroblastoma G1/S cell cycle progression via the E2F1/PTTG1 axis. Cell death & disease 13 (2) (2022)
Lijia Pan, Cheng Cheng, Peiwen Duan, Kai Chen, Yeming Wu, Zhixiang Wu
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor. Journal of experimental & clinical cancer research : CR 40 (1) (2021)
Yaoyao Gu, Xiaoxiao Hu, Xiaowei Liu, Cheng Cheng, Kai Chen, Yeming Wu, Zhixiang Wu
MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma. BMC cancer 21 (1) (2021)
Yaoyao Gu, Fan Lv, Yeming Wu, Zhixiang Wu
Angiomatoid fibrous histiocytoma with Castleman disease: A case report. Pediatric blood & cancer 68 (2) (2020)
Kai Chen, Yuanxia Cai, Cheng Cheng, Junqi Zhang, Fan Lv, Guofeng Xu, Peiwen Duan, Yeming Wu, Zhixiang Wu
MYT1 attenuates neuroblastoma cell differentiation by interacting with the LSD1/CoREST complex. Oncogene 39 (21) (2020)